Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST) ; volume:12 ; number:1 ; day:12 ; month:5 ; year:2011 ; pages:1-5 ; date:12.2011
Trials ; 12, Heft 1 (12.5.2011), 1-5, 12.2011
- Creator
-
Tanaka, Shiro
- Contributor
-
Sakamori, Yuichi
Niimi, Miyuki
Hazama, Megumi
Kim, Young H.
Yanagihara, Kazuhiro
SpringerLink (Online service)
- DOI
-
10.1186/1745-6215-12-120
- URN
-
urn:nbn:de:1111-2016050221359
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tanaka, Shiro
- Sakamori, Yuichi
- Niimi, Miyuki
- Hazama, Megumi
- Kim, Young H.
- Yanagihara, Kazuhiro
- SpringerLink (Online service)
Other Objects (12)
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
Erlotinib in pancreatic cancer
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Non-participation in breast cancer screening among previous cancer patients
Effect of present versus previous smoking on non-invasive haemodynamics
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
Erlotinib in pancreatic cancer
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Non-participation in breast cancer screening among previous cancer patients
Effect of present versus previous smoking on non-invasive haemodynamics
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
Erlotinib in pancreatic cancer
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Non-participation in breast cancer screening among previous cancer patients